IPAMORELIN 10 VIALS 10MG

What Is Ipamorelin

Ipamorelin is a selective pentapeptide growth hormone secretagogue (GHS) that mimics ghrelin’s action at the GHS-R1a receptor on pituitary somatotroph cells. Its pentapeptide structure — incorporating an Aib (alpha-aminoisobutyric acid) residue and a D-2-Nal modification — confer potent GHS-R1a binding with minimal off-target activity. This structural selectivity is why researchers who want to buy ipamorelin choose it over earlier-generation secretagogues such as GHRP-6 or GHRP-2. For a comprehensive background on ipamorelin’s pharmacology and research applications, see our CJC-1295 / Ipamorelin growth hormone guide.

For dosing protocols and reconstitution, see our ipamorelin dosage guide.

Key Research Applications

· Selective GH secretion studies: Ipamorelin activates GHS-R1a without significant ACTH or cortisol elevation, making it the gold-standard tool for isolating GH secretagogue receptor pharmacology in clean experimental models.

· Synergistic GH axis research: Most who buy ipamorelin pair it with CJC-1295 No DAC (Mod GRF 1-29) to simultaneously activate complementary GHRH and ghrelin receptor pathways for amplified GH output.

· Bone metabolism and mineral density research: Preclinical models demonstrate that ipamorelin increases bone mineral content and bone formation markers, creating relevant research tools for osteoporosis and bone density studies.

· Body composition and lean mass studies: GH pulses driven by ipamorelin support lean mass and body composition research in rodent and in vitro settings, with applications for metabolic research models.

· Age-related GH decline models: Ipamorelin is used in aging-model research to investigate restored physiological GH pulsatility, helping researchers understand the mechanisms behind age-associated GH decline.

· GHS receptor pharmacology: Researchers buy ipamorelin as a reference compound in structure-activity relationship (SAR) studies investigating next-generation selective secretagogues and GHS-R1a biased agonism.